XTalks

AUGUST 30, 2022

A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. All facilities (such as lab, pharmacy, MRI, etc.) The patients are waiting!

Trials 83

Trials Drug Delivery Drugs Gene 83

Drug Discovery World

FEBRUARY 2, 2023

Aliasger Salem, a professor at the University of Iowa’s College of Pharmacy, told NPR: “Companies need to be aware of the limitations of those technologies and their ability to identify or not identify potential toxicities.

Drugs 52

Drugs Clinical Trials Clinical Trials Cosmetics 52

The Pharma Data

MAY 16, 2021

and could change how “bioavailable” the all-important EBM triggering nutrients are. Bioavailable is a word that scientists use to describe how easy it is for your body to use a nutrient…. Now imagine that instead of having to hang your head in shame at the pharmacy…. Or explain your embarrassing symptoms to your urologist….

Production 52

Production Containment Research Doctors 52

Pharmaceutical Technology

MARCH 7, 2023

The team required narrow nanoparticle size distribution with a short processing time and a stable low temperature milling profile.

Production 130

Production Containment Bioavailability Manufacturing 130

Pharmaceutical Technology

APRIL 12, 2023

The team required narrow nanoparticle size distribution with a short processing time and a stable low temperature milling profile.

Manufacturing 130

Manufacturing Production Containment Contamination 130

Pharmaceutical Technology

DECEMBER 19, 2022

The paper concludes by noting that the potential cost reductions generated in the production of highly bioavailable APIs, as well as improved quality control, can ultimately promote production of custom formulations. Full details of the research by Fribourg University, including methods, results, and discussion, can be found here.

Production 130

Production Bioavailability Biohazard Biohazard 130

Pharmaceutical Technology

JUNE 14, 2023

Challenges for micronization Micronization has become an increasingly significant process in the pharmaceutical industry and is necessary to produce APIs with better solubility and improved bioavailability. A number of high-impact milling methods, including ball, hammer, pin, and disc mills, have been adopted to meet this need.

Containment 130

Containment Manufacturing Contract Manufacturing Bioavailability 130